Medical Pot Is Next Draw for Scientist Behind Blockbuster Drugs
- Firm set up to research medical uses of synthetic cannabis
- ‘There is massive potential,’ says immunologist Marc Feldmann
A post-harvest tech manicures finished buds at the CannTrust Holdings Inc. cannabis production facility in Fenwick, Ontario, Canada.
Photographer: Galit Rodan/BloombergThis article is for subscribers only.
A medical pioneer whose research breakthrough on inflammation led to the creation of some of the world’s top-selling drugs is embracing medical marijuana.
Marc Feldmann, an immunologist who helped discover a class of drugs that includes Humira and Remicade, has co-founded CannBioRex Pharmaceuticals, a Toronto-based company researching the potential medical uses of synthetic cannabis.